Applied DNA Attracting Banks, Insurance and Government Customers

Demonstrable ROI Is Securing New Customers and Validating Business Model


STONY BROOK, NY--(Marketwire - March 14, 2011) - Applied DNA Sciences, Inc. (OTCQB: APDN) announces new customers and inquiries within the governments and the banking and insurance industries.

Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protect brand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company's approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to "pain points" that experience the most liability.

Licensing Model Similar to Software Industry
For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN. 

License Unlocks the DNA Sequence Key
"Our model is similar to that employed by the software industry," said Dr. James Hayward, CEO of APDN. "We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value." He continued: "Our DNA sequence content is only available to our licensees. We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-in-transit transporter, but ultimately includes the financial institution and their insurer."

APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.

Proven Return on Investment
This proven ROI has brought APDN customers higher up the risk chain. "Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers," said Dr. Hayward. "We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company's history, announced in SEC filings that describe our first FY11 quarter, ending December 2010."

About APDN
APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Contact Information:

INVESTOR CONTACT:
Debbie Bailey
631-444-8090
fax: 631-444-8848

MEDIA CONTACT:
Janice Meraglia
631-444-6293
fax: 631-444-8848

FCMN Contact:
Web site: http://www.adnas.com